You are here

Company Monitoring Page for Incyte

latest headlines for company on cafepharma

Updated Incyte combo data for epacadostat/Keytruda look promising

Endpoints

Fri, 10/7/16 - 09:09 am

Tags:

Incyte, epacadostat, Keytruda

Incyte Could Be A Takeover Target, Argus Lifts Price Target To $98

Yahoo/Benzinga

Tue, 09/27/16 - 10:04 pm

Tags:

After Losing Medivation, Who Is Gilead Going After Next?

Forbes

Mon, 09/19/16 - 03:39 pm

Tags:

Medivation, Gilead Sciences, M&A, Puma Biotechnology, Kite Pharma, Incyte, Portola Pharmaceuticals

3 Biotech Stocks Could Be the Next Big Takeover Targets

24/7 Wall St

Wed, 08/31/16 - 09:20 am

Tags:

biotech, M&A, Biomarin, Incyte, Tesaro

4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss

Barron's

Tue, 08/23/16 - 11:11 am

Tags:

biotech, M&A, Gilead Sciences, Sanofi, Medivation, Incyte, Biomarin, Tesaro, Seattle Genetics

3 Plausible Buyout Scenarios Within Biotech

Seeking Alpha

Tue, 07/5/16 - 10:20 am

Tags:

biotech, Acadia, AstraZeneca, Allergan, Biogen, Teva Pharmaceutical, Biomarin, Incyte, Ironwood, Medivation, Pfizer, Relypsa, Synergy Pharmaceuticals, M&A

These 15 Biotech Companies Could Be Takeover Targets

Barron's

Wed, 06/29/16 - 12:56 pm

Tags:

biotech, M&A, Alder Biopharmaceuticals, Biomarin, Coherus Biosciences, Intercept Pharma, Ultragenyx, Seattle Genetics, Adamas Pharmaceuticals, Alexion, Clovis Oncology, Corbus Pharmaceuticals, Incyte, Prothena, Puma Biotechnology, Tesaro, Versartis

FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease (GVHD)

Yahoo

Fri, 06/24/16 - 09:15 am

Tags:

FDA, Incyte, Jakafi, breakthrough therapies, graft vs host disease

Baricitinib significantly reduces joint damage progression in rheumatoid arthritis in patients who do not respond to conventional DMARDs

Yahoo

Thu, 06/9/16 - 10:10 am

Tags:

baricitinib, Eli Lilly, Incyte, rheumatoid arthritis

Biotech: Is the Rally Real?

Barron's

Thu, 06/2/16 - 04:01 pm

Tags:

biotech, Prothena, Biomarin, Vertex Pharmaceuticals, Incyte, Celgene

3 Big Battles Brewing in Biotech

Motley Fool

Sun, 04/10/16 - 01:50 pm

Tags:

AstraZeneca, ZS-9, Relypsa, Veltassa, Synergy Pharmaceuticals, plecanatide, Linzess, Ironwood, Allergan, Incyte, Eli Lilly, baricitinib, AbbVie, Humira

How Has Incyte’s Jakafi Performed in the US?

Yahoo/Market Realist

Sat, 04/9/16 - 09:31 am

Tags:

Incyte, Jakafi, Novartis

$35M deal: Incyte licenses Lilly drug for potential new use

Bizjournals.com

Wed, 04/6/16 - 10:20 pm

Tags:

Incyte, Eli Lilly, ruxolitinib, graft vs host disease

8 Major Biopharma Events Coming Later in 2016 and in 2017

24/7 Wall St

Tue, 03/29/16 - 10:32 pm

4 BioPharma Movers That Cannot Be Ignored

24/7 Wall St

Tue, 02/16/16 - 09:58 am

Tags:

CTI BioPharma, Incyte, Biocryst, NxStage Medical

JAK inhibition for solid tumors flops, forcing Incyte to pull the plug on a slate of trials

Fierce Biotech

Thu, 02/11/16 - 08:58 pm

Tags:

Incyte, Jakafi, solid tumors, JAK inhibitors

Incyte tops Street 4Q forecasts

Yahoo/AP

Thu, 02/11/16 - 09:19 am

Tags:

Incyte, earnings

Forget Biosimilars: It's This Threat That Could Dent AbbVie's Top Line

Motley Fool

Sun, 01/31/16 - 01:37 pm

Tags:

AbbVie, biosimilars, Humira, baricitinib, rheumatoid arthritis, Incyte, Eli Lilly

A Bad Day for Biotech as Celgene, Incyte Tumble

Barron's

Thu, 01/28/16 - 09:30 pm

Tags:

Celgene, Incyte, ruxolitinib, Vertex Pharmaceuticals

Incyte's stock surges after receiving milestone payment from Eli Lilly

Marketwatch

Tue, 01/19/16 - 08:30 am

Tags:

Incyte, Eli Lilly, baricitinib

Pages

last 30 twitter posts